Answers are grounded in this paper and cite their sources.
The development of novel selective MT2 receptor ligands, together with further preclinical in vivo studies, may clarify the role of this receptor in brain function and psychopharmacology. The superfamily of GPCRs has proven to be among the most successful drug targets and, consequently, MT2 receptors have great potential for pioneer drug discovery in the treatment of mental diseases for which limited therapeutic targets are currently available.
No takes yet. Share an insight, caveat, or question.
Comai et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: